Concepedia

Author

Masahito Kotaka

National Cancer Center Hospital EastORCID

Also Known As

H Ota, Kotaka Masahito, Kotaka, M., M Kotaka, M. Kotaka, MASAHITO KOTAKA, Masahito KOTAKA, Masahito Kotaka

232

Publications

2.4K

Citations

25

H-Index

42

Concepts

All Affiliations

National Cancer Center Hospital EastAichi Cancer CenterAizawa HospitalKyushu UniversityOsaka National Hospital
MK

About

Masahito Kotaka is an author at National Cancer Center Hospital East specializing in medicine, oncology, and colorectal cancer.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

12

15

1K

2

Health Sciences

5

5

292

3

Public Health

1

1

10

4

Biostatistics

1

1

10

5

Gastroenterology

1

1

12

Masahito Kotaka

×

49

Publications

2.1K

Citations

25

H-Index

YearCitations

Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer

Daisuke Kotani, Eiji Oki, Yoshiaki Nakamura,

Nature Medicine

2023

430

Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial

Rui‐Hua Xu, Kei Muro, Satoshi Morita,

The Lancet Oncology

2018

157

Early Results of Intersphincteric Resection for Patients with Very Low Rectal Cancer: An Active Approach to Avoid a Permanent Colostomy

Norio Saito, Masato Ono, Masanori Sugito,

Diseases of the Colon & Rectum

2004

135

ctDNA-based molecular residual disease and survival in resectable colorectal cancer

Yoshiaki Nakamura, Jun Watanabe, Naoya Akazawa,

Nature Medicine

2024

132

Efficacy and Long-term Peripheral Sensory Neuropathy of 3 vs 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Colon Cancer

Takayuki Yoshino, Takeharu Yamanaka, Eiji Oki,

JAMA Oncology

2019

96

Prognostic value of desmoplastic reaction characterisation in stage II colon cancer: prospective validation in a Phase 3 study (SACURA Trial)

Hideki Ueno, Megumi Ishiguro, Eiji Nakatani,

British Journal of Cancer

2021

94

Phase Ib/II Study of Biweekly TAS-102 in Combination with Bevacizumab for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies (BiTS Study)

Hironaga Satake, Takeshi Kato, Koji Oba,

The Oncologist

2020

61

Association of circulating tumor DNA dynamics with clinical outcomes in the adjuvant setting for patients with colorectal cancer from an observational GALAXY study in CIRCULATE-Japan.

Masahito Kotaka, Hiromichi Shirasu, Jun Watanabe,

Journal of Clinical Oncology

2022

61

Oxaliplatin-based adjuvant chemotherapy duration (3 versus 6 months) for high-risk stage II colon cancer: the randomized phase III ACHIEVE-2 trial

Kentaro Yamazaki, Takeharu Yamanaka, Manabu Shiozawa,

Annals of Oncology

2020

50

Prognostic Impact of Primary Tumor Location on Clinical Outcomes of Metastatic Colorectal Cancer Treated With Cetuximab Plus Oxaliplatin-Based Chemotherapy: A Subgroup Analysis of the JACCRO CC-05/06 Trials

Yu Sunakawa, Wataru Ichikawa, Akihito Tsuji,

Clinical Colorectal Cancer

2016

46

Page 1